Skip to content

Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement

Prospective, Multicenter, Observational Study Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biosynthetic Material for Midline Fascial Closure Reinforcement

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01325792
Acronym
COBRA
Enrollment
104
Registered
2011-03-30
Start date
2011-02-28
Completion date
2014-12-31
Last updated
2015-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventral Incisional Hernia

Keywords

Complex ventral incisional hernia repair, reapproximation of the rectus abdominis muscle, retrorectus or intraperitoneal placement technique, mobility for midline fascial closure

Brief summary

Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.

Detailed description

The study will evaluate the performance of the biosynthetic mesh when used to reinforce the midline fascial closure in single-staged open complex ventral incisional hernia repair. It is designed to test the null hypothesis that the two year recurrence rate associated with the device is greater than or equal to 50% vs the alternative hypothesis that the two year recurrence rate is less than 50%.

Interventions

DEVICEGORE® BIO-A® Tissue Reinforcement

Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.

Sponsors

W.L.Gore & Associates
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects will be informed about the study, and will have read; understood and signed the informed consent and authorization to use their PHI, as applicable * Subjects willing and able to submit to postoperative follow-up evaluations including quality of life assessments up to 24 months after surgery * Subjects of either gender that are at least the age of 18 years * Subjects will have a Body-Mass Index (BMI) of \< 40 * Subjects will be undergoing single-staged open complex ventral incisional hernia repair with the retrorectus or intraperitoneal placement technique of the GORE® BIO-A® Tissue Reinforcement * Subjects in which intraoperatively their surgical field/wound is characterized either a Type 2 or Type 3 in Table 1 in Section 12.0 * Subjects with a hernia defect \> 9 cm2 large when measured intraoperatively * Subjects in which the required mobility for midline fascial closure without excessive tension to reapproximate the rectus abdominis muscle intraoperatively can be achieved * Subjects in which one unit of GORE® BIO-A® Tissue Reinforcement will adequately reinforce the midline fascial closure with at least 4 cm of overlap laterally

Exclusion criteria

* Subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study * Subjects with a BMI \> 40 * Subjects with evidence of pre-existing systemic infections * Subjects with cirrhosis or are currently being treated with dialysis * Subjects with a wound-healing disorder * Subjects with autoimmune disorder requiring \> 10mg of a corticosteroid per day * Subjects who are immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy * Subjects with a hernia defect \< 9 cm2 large when measured intraoperatively * Subjects with a hernia defect requiring more than one unit of GORE® BIO-A® Tissue Reinforcement * Subjects in which intraoperatively there is an inability to achieve retrorectus or intraperitoneal placement of the device * Subjects in which a midline fascial closure without excessive tension cannot be achieved * Subjects in which intraoperatively their surgical field/wound is characterized either a Type 1 or Type 4 in the Table 1 in Section 12 * Subjects in need of concomitant surgical procedures other than indicated in the protocol as acceptable * Subject in which their complex ventral incisional hernia repair requires more than one operation to reduce hernia and close fascia, including serial excision procedures - requiring subsequent surgery to complete their hernia repair * Subjects with a hernia repair requiring an emergent procedure, such as strangulated bowel * Subjects in which intraoperatively untreated cancer was found

Design outcomes

Primary

MeasureTime frameDescription
Hernia Recurrence Rateat about 24 monthsInvestigator confirmed hernia recurrence by physical examination

Secondary

MeasureTime frameDescription
Early and Long-term Complication Ratesafter surgery (day 1) to 24 monthsSurgical site abdominal wound event rate

Countries

Netherlands, United States

Participant flow

Recruitment details

104 subjects recruited from 9 sites in the US and Netherlands between March 2011 and December 2012

Participants by arm

ArmCount
Single-staged Open Complex Ventral Incisional Hernia Repair
primary or recurrent anterior abdominal wall hernia GORE BIO-A Tissue Reinforcement: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure
104
Total104

Baseline characteristics

CharacteristicSingle-staged Open Complex Ventral Incisional Hernia Repair
Age, Continuous57.7 years
STANDARD_DEVIATION 13.4
BMI (Body Mass Index)27.6 kg/m^2
STANDARD_DEVIATION 6.1
Sex: Female, Male
Female
62 Participants
Sex: Female, Male
Male
42 Participants
Wound Classification
Clean-contaminated
24 participants
Wound Classification
Contaminated
80 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
25 / 104
serious
Total, serious adverse events
3 / 104

Outcome results

Primary

Hernia Recurrence Rate

Investigator confirmed hernia recurrence by physical examination

Time frame: at about 24 months

ArmMeasureValue (NUMBER)
Single-staged Open Complex Ventral Incisional Hernia RepairHernia Recurrence Rate17.3 % of subjects with recurrent hernia
Secondary

Early and Long-term Complication Rates

Surgical site abdominal wound event rate

Time frame: after surgery (day 1) to 24 months

ArmMeasureValue (NUMBER)
Single-staged Open Complex Ventral Incisional Hernia RepairEarly and Long-term Complication Rates29.8 % of subjects with events

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026